论文部分内容阅读
在新药研发临床前研究阶段,建立更接近人体内代谢情况的体外模型尤为重要,旨在减少实验动物的数量,并对药物在人体内的代谢情况进行更为准确的预测.利用微流控技术,通过结合亚细胞组分、肝细胞以及肝脏组织,可以建立更加完善的体外肝脏代谢模型,从而开展药物代谢的相关研究.微流控平台通过对流体的精确控制可建立动态培养环境,通过设计3D结构可模拟人体内的肝组织结构.此外,在芯片上进行不同细胞的共培养还可模拟人体器官的互作,提升体外模型的仿生性.本综述更新了自201 1年以来基于微流控技术构建的肝脏药物代谢模型,并分别对不同的芯片载体(亚细胞组分、原代肝细胞及组织切片)进行了综述.“,”In pre-clinical phase of new drug development,it is particularly important to establish an in vitro model to mimic the metabolism situation of human body.The aim of the in vitro model is to reduce the usage of experimental animals and to make a more accurate prediction of the drag metabolism in vivo.Microfluidic chip is an emerging technology to establish predictive models.By integrating subcellular fractions,hepatocytes or liver tissue in the microfluidic chips,more predictive in vitro metabolism models can be established for drug development.The microfluidic platform offers dynamic and controlled fluids,as well as sophisticated liver tissue assembly to remodel the physiological and pathological microenvironment of liver in the human body.This review updates the microfluidic-based liver drug metabolism models since 2011,and summarizes the development of different models based on different chip vectors (subcellular components,primary hepatocytes,and tissue sections).It serves as a guide for newcomers to this dynamic field.